\
&
Contact us
AI Continent Deployment: Best use of technologies
The LDT4SSC (Local Digital Twins for Smart and Sustainable Communities) project has opened a new cascade funding call to local network of cities, regions, and digital innovators. This call supports co-funding for three Work Strands with a minimum available budget of 10.8 Million euros: - Work strand 1 - interconnecting existing LDTs: At least... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.